This study aims to evaluate the role of a specific gene polymorphism, Cytidine/Uridine Monophosphate Kinase 1 (CMPK1) rs1044457, in predicting the response to gemcitabine‐based chemotherapy in patients with NSCLC. The gene discussed is CMPK1; the disease is non-small cell lung carcinoma.